Related Experiment Video
Updated: Dec 9, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
COURAGE, ORBITA, and ISCHEMIA: Percutaneous Coronary Intervention for Stable Coronary Artery Disease
1Barts Health NHS Trust, The Royal London Hospital, 80 Newark Street, London E1 2ES, UK.
Insights
Percutaneous coronary intervention (PCI) primarily offers symptomatic relief for stable coronary artery disease (CAD), not improved survival. Risk-reducing medications are key for better outcomes in patients with CAD.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Stable coronary artery disease (CAD) management involves understanding the interplay between stenosis, ischemia, and angina.
- Percutaneous coronary intervention (PCI) is a common revascularization strategy for CAD.
Purpose of the Study:
- To review landmark trials evaluating the role of PCI in stable CAD.
- To clarify the indications and outcomes associated with PCI in stable CAD.
Main Methods:
- Review of pivotal clinical trials comparing PCI to medical therapy or placebo in stable CAD.
- Analysis of data regarding anginal symptom relief, mortality, and myocardial infarction rates.
Main Results:
- Anginal relief is the primary benefit of PCI in stable CAD.
- PCI has not demonstrated significant improvements in mortality or myocardial infarction rates, even with substantial ischemia.
- Placebo effects appear significant in PCI trials for stable CAD.
Conclusions:
- PCI in stable CAD is mainly indicated for symptom management.
- Optimal medical therapy remains crucial for improving long-term outcomes and reducing cardiovascular events in stable CAD.
- Further research may refine the selection of patients who benefit most from PCI.
Abstract:
This review article summarizes key landmark trials that have shaped understanding of the role of percutaneous coronary intervention (PCI) in stable coronary artery disease (CAD). The relationship between stenosis, ischemia, and angina is more complex than first imagined. Anginal relief remains the primary indication for PCI in stable CAD. The first placebo-controlled PCI trial showed a surprisingly small effect size, suggesting a significant placebo effect. PCI in stable CAD has not been shown to improve mortality or overall myocardial infarction rates, even in the presence of significant ischemia. Rather, risk reduction medical therapy remains the main intervention for improving outcomes.
More Related Videos
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
12:00Evaluation of a Novel Laser-assisted Coronary Anastomotic Connector - the Trinity Clip - in a Porcine Off-pump Bypass Model
Published on: November 24, 2014
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease I: Introduction
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies